Strontium ranelate, an investigational drug with a novel mechanism of action against osteoporosis, appears to reduce the incidence of vertebral fractures in postmenopausal women, new research suggests.
The findings of a phase III trial were presented here at the American College of Rheumatology (ACR) 66th Annual Scientific Meeting on Monday. “Most of the compounds that have been developed
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!